Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848472 | 1.00 | STING1 (0.45) | STING1PTGDR2KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5848481 | 1.00 | STING1 (0.45) | STING1PTGDR2KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5848110 | 0.88 | STING1 (0.42) | STING1PTGDR2KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5848113 | 0.88 | STING1 (0.42) | STING1PTGDR2KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5848117 | 0.88 | STING1 (0.42) | STING1PTGDR2KMT2ASLC6A2SLC6A4 | |
| SCHEMBL5848241 | 0.81 | SMN1; SMN2 (0.56) | PTGDR2TSHRSMN1; SMN2 | |
| SCHEMBL5848238 | 0.81 | SMN1; SMN2 (0.56) | PTGDR2TSHRSMN1; SMN2 | |
| SCHEMBL5848245 | 0.81 | SMN1; SMN2 (0.56) | PTGDR2TSHRSMN1; SMN2 | |
| SCHEMBL11001307 | 0.77 | TRPV1 (0.44) | PTGDR2 | |
| SCHEMBL5847275 | 0.73 | OPRK1 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034051-B2 | Fused bicyclic carboxamide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2006-04-25 | — | — | US | disclosed |
| WO-2005023799-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054630-A1 | Fused bicyclic carboxamide derivatives and methods of their use | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CPS1 | STING1 4509/4885PTGDR2 1500/4885KMT2A 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.